SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.
On March 15, 2023, at 2:00 p.m. PST, Kevin Herde, Chief Financial Officer, and Deborah Barbara, Vice President, Strategy and Business Development will participate in a fireside chat at the Barclays Global Healthcare Conference being held in Miami, Florida.
On March 21, 2023, at 9:45 a.m. PST, Carl Hull, Chairman of the Board and Interim CEO will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum being held virtually.
A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events. An archived version of the webcasts will also be available on the Maravai website following the completion of each event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Last Trade: | US$4.57 |
Daily Change: | 0.01 0.22 |
Daily Volume: | 3,149,906 |
Market Cap: | US$648.210M |
January 08, 2025 December 05, 2024 November 07, 2024 November 07, 2024 September 24, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load